These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30485535)

  • 1. Safety and tolerability of high-intensity statin therapy in heart transplant patients receiving immunosuppression with tacrolimus.
    Heeney SA; Tjugum SL; Corkish ME; Hollis IB
    Clin Transplant; 2019 Jan; 33(1):e13454. PubMed ID: 30485535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients.
    Penson MG; Fricker FJ; Thompson JR; Harker K; Williams BJ; Kahler DA; Schowengerdt KO
    J Heart Lung Transplant; 2001 Jun; 20(6):611-8. PubMed ID: 11404165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival.
    Younas N; Wu CM; Shapiro R; McCauley J; Johnston J; Tan H; Basu A; Schaefer H; Smetanka C; Winkelmayer WC; Unruh M
    BMC Nephrol; 2010 Apr; 11():5. PubMed ID: 20359353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus.
    Taylor DO; Barr ML; Radovancevic B; Renlund DG; Mentzer RM; Smart FW; Tolman DE; Frazier OH; Young JB; VanVeldhuisen P
    J Heart Lung Transplant; 1999 Apr; 18(4):336-45. PubMed ID: 10226898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of atorvastatin in heart transplant recipients.
    Patel DN; Pagani FD; Koelling TM; Dyke DB; Baliga RR; Cody RJ; Lake KD; Aaronson KD
    J Heart Lung Transplant; 2002 Feb; 21(2):204-10. PubMed ID: 11834348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
    Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
    J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins and the risk of cancer after heart transplantation.
    Fröhlich GM; Rufibach K; Enseleit F; Wolfrum M; von Babo M; Frank M; Berli R; Hermann M; Holzmeister J; Wilhelm M; Falk V; Noll G; Lüscher TF; Ruschitzka F
    Circulation; 2012 Jul; 126(4):440-7. PubMed ID: 22761452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation.
    Crespo-Leiro MG; Paniagua MJ; Marzoa R; Grille Z; Naya C; Flores X; Rodriguez JA; Mosquera V; Franco R; Castro-Beiras A
    Transplant Proc; 2008 Nov; 40(9):3060-2. PubMed ID: 19010194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of rosuvastatin in heart transplant patients with hypercholesterolemia and therapeutic failure of other statin regimens: short-term and long-term efficacy and safety results.
    Barge-Caballero G; Barge-Caballero E; Marzoa-Rivas R; Paniagua-Martín MJ; Barrio-Rodríguez A; Naya-Leira C; Blanco-Canosa P; Grille-Cancela Z; Vázquez-Rodríguez JM; Crespo-Leiro MG
    Transpl Int; 2015 Sep; 28(9):1034-41. PubMed ID: 25864881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin intensity and risk for cardiovascular events after heart transplantation.
    Golbus JR; Adie S; Yosef M; Murthy VL; Aaronson KD; Konerman MC
    ESC Heart Fail; 2020 Oct; 7(5):2074-2081. PubMed ID: 32578953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uncertain benefit of statins in pediatric heart transplant recipients: A PHTS analysis.
    Townsend M; Khoury M; Koehl D; Kirklin JK; Cantor R; Beasley G; Chen CY; Boyle G; Parent JJ; Baez Hernandez N; Halnon N
    J Heart Lung Transplant; 2024 May; 43(5):703-713. PubMed ID: 38065240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation.
    Wissing KM; Unger P; Ghisdal L; Broeders N; Berkenboom G; Carpentier Y; Abramowicz D
    Transplantation; 2006 Sep; 82(6):771-8. PubMed ID: 17006324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia.
    Almutairi F; Peterson TC; Molinari M; Walsh MJ; Alwayn I; Peltekian KM
    Liver Transpl; 2009 May; 15(5):504-8. PubMed ID: 19399742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin therapy is not associated with improved outcomes after heart transplantation in children and adolescents.
    Greenway SC; Butts R; Naftel DC; Pruitt E; Kirklin JK; Larsen I; Urschel S; Knecht K; Law Y
    J Heart Lung Transplant; 2016 Apr; 35(4):457-65. PubMed ID: 26746989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.
    Aliabadi AZ; Mahr S; Dunkler D; Grömmer M; Zimpfer D; Wolner E; Grimm M; Zuckermann AO
    Transplantation; 2008 Dec; 86(12):1771-6. PubMed ID: 19104420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance.
    Kennedy SP; Barnas GP; Schmidt MJ; Glisczinski MS; Paniagua AC
    J Clin Lipidol; 2011; 5(4):308-15. PubMed ID: 21784377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ezetimibe is effective in the treatment of persistent hyperlipidemia of renal allograft recipients.
    Savvidaki E; Koukoulaki M; Benou A; Roumeliotou M; Fourtounas C; Kalliakmani P; Papachristou E; Vlachojannis JG; Goumenos D
    Clin Nephrol; 2011 Feb; 75(2):107-12. PubMed ID: 21255539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for minimizing hyperlipidemia after cardiac transplantation.
    Kirklin JK; Benza RL; Rayburn BK; McGiffin DC
    Am J Cardiovasc Drugs; 2002; 2(6):377-87. PubMed ID: 14727953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ezetimibe effectively lowers LDL-cholesterol in cardiac allograft recipients on stable statin therapy.
    Konstandin MH; Blessing E; Doesch A; Ammon K; Koch A; Wabnitz GH; Gleissner CA; Remppis A; Katus HA; Dengler TJ
    Clin Transplant; 2008; 22(5):639-44. PubMed ID: 18492070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.